Celsion Corporation Культура компании

Mr. Michael H. Tardugno has been the Chief Executive Officer and President of Celsion Corporation since January 3, 2007 and has been its Executive Chairman since October 7, 2014. Mr. Tardugno has an extensive experience in Pharmaceutical industry leadership. He served as Senior Vice President and General Manager of Mylan Laboratories Inc., since February 2005. From 1998 to 2005, he served as an Executive Vice President and a Founding member of Management of Songbird Hearing, Inc., where he forged a number of significant agreements with major US and International partners in the development and commercialization of the world's first disposable hearing aid. Mr. Tardugno served as a Senior Vice President of ConvaTec, a division of Bristol-Myers Squibb from 1996 to 1998 and its Vice President of Technology Development & Manufacturing of Bausch & Lomb from 1989 to 1995. He started his career with Abbott Laboratories holding positions in pharmaceutical operations, principally as plant manager for its Ross Laboratories Division nutritional business. Mr. Tardugno has been a Director at Celsion Corporation since January 22, 2007. He served as a Director of Theranostics Health, LLC. Mr. Tardugno holds a B.S. in Biology and Chemistry minor from St. Bonaventure University and attended Program for Management Development from Harvard Business School.

Dr. Nicholas Borys, M.D., has been the Chief Medical Officer and Senior Vice President of Celsion Corp., since October 1, 2007 and June 2014 respectively. Dr. Borys manages the clinical development program for Celsion Corp. Dr. Borys served as the Chief Medical Officer of Molecular Insight Pharmaceuticals Inc., from June 2004 to April 18, 2007. Dr. Borys joined Cytogen Corp., as a Vice President of Medical Affairs in January 2000. He served as a Vice President of Medical Affairs at EUSA Pharma (USA) Inc. He served as a Vice President of Celsion Corp., since October 1, 2007. He served as a Vice President and Medical Director at Anthra Pharmaceuticals from October 1998 to January 2000. From December 1992 to July 1998, Dr. Borys served as a Director of Medical Affairs at Amersham Healthcare Inc. From 1987 to 1992, he served as a Director of Medical and Clinical Services at Hoffmann-La Roche Inc. He has over 16 years of experience in pharmaceutical development. His background includes strategic planning and management of all phases of clinical development for Food and Drug Administration (FDA) approval. From 2002 to 2004, he served as the Chief Medical Officer of Taiho Pharma, where he was responsible for clinical development worldwide. He holds a BA from Rutgers University and an MD from American University of the Caribbean.

Mr. Timothy J. Tumminello, CPA, has been the Chief Accounting Officer and Controller of Celsion Corp. since June 25, 2010 and January 6, 2010 respectively. Mr. Tumminello served as an Interim Chief Accounting Officer and Controller of Celsion Corp. from January 6, 2010 to June 25, 2010 and served as its Secretary. Mr. Tumminello served as an Assistant Controller of Celsion Corp. since April 2009. Mr. Tumminello served as Vice President and Interim Principal Financial Officer of IC Isaacs & Co. Inc. since May 2000 and December 2007 respectively. Mr. Tumminello has been the Controller of IC Isaacs & Co. Inc. since May 2000 and serves as its Secretary. He started his employment with IC Isaacs & Co. Inc. in May 1997 and served as its Assistant Controller until July 1999. From July 1999 to May 2000, he served as the Chief Financial Officer of Graphtec, Inc., a subsidiary of Consolidated Graphics, Inc. Mr. Tumminello served at Baltimore office of Deloitte & Touche LLP from January 1991 to May 1997. Mr. Tumminello is a Certified Public Accountant.

Dr. Khursheed Anwer, Ph.D., M.B.A., has been the Chief Scientific Officer and Executive Vice President at Celsion Corporation since June 20, 2014. Before joining Celsion, Dr. Anwer served as President and Chief Scientific Officer of Expression Genetics, Inc. (formerly, EGEN) from June 2009 to June 2014 and its Vice President of Research and Development from July 2002 to June 2009. Dr. Anwer Joined Expression Genetics in July 2002. Before joining EGEN, Dr. Anwer served as Director of Pre-Clinical Development at Valentis, Inc. from July 2000 to June 2002. From October 1993 to June 2000, he held several positions at GeneMedicine, Inc., where he led several research projects in the area of non-viral gene therapy. Dr. Anwer served as a member of the board of directors of EGEN from December 2010 to June 2014. Dr. Anwer is an adjunct faculty member in the Biology Department at the University of Alabama in Huntsville and a board member of the University of Alabama Business School, MBA STEP path. Dr. Anwer holds a Ph.D. in physiology/pharmacology from Ohio University and has received post-doctoral training from the University of Texas Health Science Center at Houston.

Mr. Jeffrey W. Church, also known as Jeff, has been the Senior Vice President of Corporate Strategy and Investor Relations at Celsion Corporation since July 8, 2011 and has been its Chief Financial Officer since July 2010 and its Corporate Secretary since July 2010. Mr. Church served as the Chief Financial Officer, Vice President and Corporate Secretary at Celsion Corp. from July 6, 2010 to July 8, 2011. Mr. Church served as Chief Financial Officer of Alba Therapeutics Corp. since April 23, 2007. Mr. Church served as Chief Financial Officer of Novavax Inc. from September 5, 2006 to April 2007 and served as its Vice President and Treasurer since September 5, 2006. Mr. Church served as Corporate Secretary of Novavax Inc. since September 2006 and served as its Principal Accounting Officer. Mr. Church served as Chief Financial Officer, Principal Accounting Officer, Treasurer and Corporate Secretary of Genvec Inc. from 1988 to August 31, 2006. He served as Executive Vice President and Chief Financial Officer of Biospherics Inc. from September 1997 to August 1998. He was employed with Meridian Medical Technologies, Inc. In addition to his Chief Financial Officer duties at Meridian Medical Technologies, Inc. where he had been responsible for one of Genvec Inc.'s three operating units. He spent 7 years with PricewaterhouseCoopers as Audit Manager. He has an enormous amount of financial expertise and industry experience and has more than 30 years of experience. He joined Survival Technology, Inc. in April 1986, as Corporate Controller and became Vice President of Finance and Chief Financial Officer in June 1988; Senior Vice President of Finance and Chief Financial Officer in November 1994. He served with the accounting firm of Price Waterhouse LLP for 7 years. Mr. Church is a Certified Public Accountant and received his B.S. in Accounting, Summa Cum Laude from University of Maryland.

Dr. Edwin De Wit, M.D. has been Senior Vice President and Head of Medical for Europe at Celsion Corp., since November 03, 2015. Dr. De Wit has over 20 years of experience in clinical operations and research in the pharma and biotech industry. He has international experience and expertise in pharmaceutical strategy and in the design and execution of large oncology programs. Dr. De Wit served as Head of Medical - Europe & Middle East and Africa at Onyx Pharmaceuticals, a subsidiary of Amgen, focused on developing cancer therapeutics. In this role, he led the design and implementation of strategic clinical development and medical affairs plans for Onyx's Oncology and Hematology operations at Onyx Pharmaceuticals regional headquarters, including the initiation of an Early Access Program in Europe. Prior to Onyx, Dr. De Wit served as Executive Director of Oncology Clinical Research at Boehringer Ingelheim from 2008 to 2012 where he was responsible for the development of novel anti-cancer agents in various stages of development. He also held leadership roles in the area of Oncology Clinical Development at Bristol-Myers Squibb from 2005 to 2008 and at Pfizer from 2002 to 2005, after having spent over 10 years in clinical operations roles at Smithkline Beecham, Ferring Pharmaceuticals and Vitaresc Biotech.